These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31586203)

  • 1. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
    Panoutsopoulou K; Avgeris M; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Vanderstichele A; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Carcinogenesis; 2020 Jun; 41(4):442-451. PubMed ID: 31586203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients.
    Pal R; Choudhury T; Ghosh M; Vernakar M; Nath P; Nasare VD
    Clin Transl Oncol; 2024 Jul; 26(7):1716-1724. PubMed ID: 38472557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
    PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
    Li Y; Li L
    J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer.
    Panoutsopoulou K; Liu Y; Avgeris M; Dreyer T; Dorn J; Magdolen V; Scorilas A
    Clin Biochem; 2023 Apr; 114():43-51. PubMed ID: 36502883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.
    Meng X; Joosse SA; Müller V; Trillsch F; Milde-Langosch K; Mahner S; Geffken M; Pantel K; Schwarzenbach H
    Br J Cancer; 2015 Nov; 113(9):1358-66. PubMed ID: 26393886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer.
    Xu YZ; Xi QH; Ge WL; Zhang XQ
    Asian Pac J Cancer Prev; 2013; 14(2):1057-60. PubMed ID: 23621186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished miR-613 expression as a novel prognostic biomarker for human ovarian cancer.
    Zhang X; Zhang H
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):837-41. PubMed ID: 27010138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low miR-498 expression levels are associated with poor prognosis in ovarian cancer.
    Cong J; Liu R; Wang X; Wang J; Wang H; Hou J
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4762-5. PubMed ID: 26744867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
    Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
    Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
    Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
    Halvorsen AR; Kristensen G; Embleton A; Adusei C; Barretina-Ginesta MP; Beale P; Helland Å
    Dis Markers; 2017; 2017():3098542. PubMed ID: 28293063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of a novel circulatory RNA-based biomarker panel expression in ovarian cancer.
    El-Shal AS; Matboli M; Abdelaziz AM; Morsy AA; Abdelbary EH
    IUBMB Life; 2019 Dec; 71(12):2031-2047. PubMed ID: 31520466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
    Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
    Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.